News

Immunis said it entered into an exclusive deal with Toray for the rights to develop and commercialize a potential treatment for dyskinesia, the involuntary movements associated with long-term use of levodopa in people with Parkinson’s disease, and has submitted an application to the U.S. Food…

Oncodesign Precision Medicine (OPM) has been awarded a $6.92 million research grant from The Michael J. Fox Foundation (MJFF) to prepare its LRRK2 inhibitor, OPM-201, for a clinical study in people with early Parkinson’s disease. The funding follows OPM’s integration into MJFF’s LRRK2 Investigative Therapeutics Exchange…

Regulators in the U.S. and China have granted Xellsmart permission to start clinical testing of its experimental stem cell therapy in people with multiple system atrophy-Parkinsonian type (MSA-P). This is the fourth clinical trial program for Xellsmart’s stem cell therapy platform to have received regulatory clearance from both the…

Japan’s Ministry of Health, Labour and Welfare has granted conditional approval to Amchepry, Sumitomo Pharma’s stem cell-derived therapy designed to replace dopamine-producing nerve cells, for people with Parkinson’s disease who do not respond adequately to existing treatments such as levodopa. The approval was based on results from a …

A fully implanted brain device can identify when people with Parkinson’s disease are walking during their everyday lives, according to a new study from the University of California, San Francisco (UCSF). By recording neural activity from movement-related brain regions while patients went about their normal routines at home, researchers…

Impaired cellular energy may interfere with how dopamine — the key chemical messenger that is in short supply in Parkinson’s disease — is packaged and handled inside nerve cells, a new study has found. According to the researchers, such disruptions, and a resulting energy shortage, may promote the formation…

The Silvi Foundation has officially launched as a nonprofit organization dedicated to advancing research into Parkinson’s disease and other neurodegenerative conditions. As its first initiative, the newly established foundation has awarded a $100,000 grant to the Institute for Neurodegenerative Diseases (IND) to support research on blood-based biomarkers…

The Parkinson’s Foundation has released its new national strategy dedicated to improving care for people with Parkinson’s disease by focusing on practical, patient-centered solutions that the nonprofit says will address the real challenges now facing the U.S. community. The new strategy, dubbed Parkinson’s Care and Innovation: A…

Quitting smoking was linked to a greater risk of Parkinson’s disease compared with continuing to smoke, but it was also associated with a smaller risk of death — especially among those who quit and remained smoke-free — in a large-scale study conducted in South Korea. These new data come…

Despite strong evidence linking paraquat to Parkinson’s disease, the herbicide is still legal in the U.S., although some states are moving to restrict or ban it to protect public health. Advocates, including the American Parkinson’s Disease Association (APDA), are also urging action to align federal policy with more…